Compare Citius Pharmaceuticals Inc (CTXR) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Trade Desk Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Trade Desk Inc trades at $12.1 (market cap $5.83B). The key difference: Trade Desk Inc is far larger — about 428× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 15,864,392). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Trade Desk Inc for 72 Days on average.
| CTXR | TTD | |
|---|---|---|
Market Cap | $13.62M | $5.83B |
Volume | 132,438 | 15,864,392 |
Sector | Health | Media |
52-Week High | $1.82 | $54.13 |
52-Week Low | $0.48 | $11.92 |
Typical Hold Time | 17 Days | 72 Days |
Enterprise Value | $3.79M | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
The Trade Desk (TTD) trades at $12.08, down 0.08% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $2.90B and net income of $443.30M, though 2026 guidance indicates slowing growth. Valuation metrics appear attractive with P/E of 0.15 and P/S of 0.02. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions.
Investment outlook remains cautious despite attractive valuations. The stock faces headwinds from slowing revenue growth and intense competition, but maintains leadership in programmatic advertising. Analyst consensus suggests 22% upside to $14.72 target, though mixed ratings reflect uncertainty about near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
